AstraZeneca formally ends TC-5214 partnership with Targacept
This article was originally published in Scrip
Executive Summary
It couldn't have been a surprise on 30 April when Targacept notified its investors that AstraZeneca will terminate the companies' 2009 collaboration and license agreement to develop and commercialize TC-5214 as an adjunct to antidepressant therapy for patients with major depressive disorder.